Santen Pharmaceutica (SNPHF) 13.9000 $SNPHF
Ocular Hypertension - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nbvbk4/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerie Pharmaceuticals, Inc. - Allergan, Inc. - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - Can-Fite BioPharma Ltd. - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Merck & Co., Inc. - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. For more information visit http://www.researchandmarkets.com/research/nbvbk4/ocular
CANF: 2.00 (+0.09), AGN: 312.13 (+8.03), ITEK: 5.11 (+0.25), MRK: 57.95 (+0.57), AERI: 17.80 (+0.12), OCUL: 20.82 (+0.73)
Uveitis Pipeline Review, H1 2015
M2 - Thu Jun 11, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xvvmhf/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aciont Inc. - Apitope International NV - BBB Therapeutics B.V. - Can-Fite BioPharma Ltd. - Clearside BioMedical, Inc. - Effimune SAS - Eleven Biotherapeutics Inc. - Endocyte, Inc. - Enzo Biochem, Inc. - EyeGate Pharmaceuticals, Inc. - ForSight VISION4, Inc. - HanAll Biopharma Co., Ltd. - Icon Bioscience, Inc. - IMMD Inc. - Johnson & Johnson - Neuroptis Biotech - Novartis AG - Ocata Therapeutics, Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. - Pfizer Inc. - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SynDevRx, Inc. - TxCell SA - Virogenomics, Inc. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/xvvmhf/uveitis
OCAT: 5.22 (+0.14), PFE: 34.36 (+0.50), CANF: 2.00 (+0.09), JNJ: 99.53 (+1.13), ECYT: 5.43 (+0.17), ENZ: 3.00 (+0.04), ABBV: 69.23 (+1.26), REGN: 526.01 (+16.98), XOMA: 4.72 (+0.23), NVS: 103.22 (+3.20)
Global Acute Pain Pipeline Report 2015
M2 - Thu Jun 04, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gndxls/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt plc - MEDRx Co., Ltd. - Merck & Co., Inc. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Rottapharm SpA - Santen Pharmaceutical Co., Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. - Thar Pharmaceuticals, Inc. - Trevena, Inc. - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/gndxls/acute_pain
ACRX: 4.20 (+0.02), TRVN: 6.51 (+0.61), KMPH: 17.95 (-0.08), MRK: 57.95 (+0.57), PCRX: 67.54 (+0.20), NKTR: 11.40 (+0.22)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015
M2 - Wed May 27, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vmksm/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - EyeGate Pharmaceuticals, Inc. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kainos Medicine, Inc. - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Neuroptis Biotech - NovaBay Pharmaceuticals, Inc. - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - SIFI S.p.A For more information visit http://www.researchandmarkets.com/research/3v...njunctivit
OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), CLTX: 0.49 (-0.02)
Santen Announces Assignment of Its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma Co., Ltd.
GlobeNewswire - Tue May 12, 2:53AM CDT
Santen Pharmaceutical Co., Ltd. ("Santen"
announced today that it has resolved at its board of directors meeting held on May 12, 2015 to enter an agreement with Showa Yakuhin Kakou Co., Ltd. ("Showa Yakuhin" and Hyperion Pharma Co., Ltd. ("Hyperion" to assign its anti-rheumatic pharmaceuticals business to Hyperion, under a simplified company-split method under the Company Act of Japan ("Assignment" . On the same date, Santen, Hyperion, and Showa have entered into the agreement on the Assignment.
Santen Reports Consolidated Performance for the Fiscal Year Ended March 31, 2015
GlobeNewswire - Tue May 12, 2:53AM CDT
Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange Code:4536) (Santen) today announced consolidated performance for fiscal 2014 (ended March 31, 2015) as well as guidance for fiscal 2015 (ending March 31, 2016).
R-Tech Ueno: Announcement on Acquisition of the Right to Develop and Commercialize DE-105 from Santen Pharmaceutical Co., Ltd.
Business Wire - Mon Apr 27, 2:03AM CDT
R-Tech Ueno (JASDAQ:4573)
Santen Announces Approval of Ikervis for EU Marketing Authorization
GlobeNewswire - Wed Mar 25, 3:45AM CDT
Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European Commission (EC). Ikervis is approved for treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.
European Medicines Agency Accepts Santen's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment
GlobeNewswire - Mon Mar 02, 2:24AM CST
Santen Pharmaceutical Co., Ltd. announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Application (MAA) filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment. The MAA filing marks the beginning of a regulatory review process for intravitreal sirolimus, which has the potential to address an unmet need in the European Union (EU) where NIU of the posterior segment is a leading cause of blindness.
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 5.22 (+0.14), ITEK: 5.11 (+0.25), NBS: 2.25 (-0.09), FOMX: 11.18 (+0.22), AERI: 17.80 (+0.12), OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), CANF: 2.00 (+0.09), ACAD: 43.94 (+1.76), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), OHRP: 2.27 (-0.07), CBMG: 29.80 (+0.31)
DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product
PR Newswire - Tue Dec 16, 7:00AM CST
DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's SABER® technology to deliver an ophthalmology drug.
DRRX: 2.48 (+0.15)
Increase of Capital for a Consolidated Subsidiary in Europe
GlobeNewswire - Thu Sep 25, 4:32AM CDT
Santen Pharmaceutical Co., Ltd. (Osaka, hereinafter "Santen" hereby announces that it was resolved at the Board of Director meeting held on September 25, 2014 to increase capital for Santen Holdings EU B.V., a consolidated wholly owned holding company in Europe.
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 17.80 (+0.12)
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
CANF: 2.00 (+0.09), ECYT: 5.43 (+0.17), ENZ: 3.00 (+0.04), PFE: 34.36 (+0.50), ABBV: 69.23 (+1.26), XOMA: 4.72 (+0.23), NVS: 103.22 (+3.20)
Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Aug 12, 6:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6chxqf/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering. The Global Macular Edema market will grow at a CAGR of 9.1% over the period 2014-2018. NICE issues and updates technology appraisals and clinical guidelines to recommend appropriate and effective treatments for different diseases. It plays a role in increasing drug sales. In January 2013, NICE recommended Lucentis for the treatment of DME. This recommendation superseded the November 2011 guidance, which concluded that recommending Lucentis was not effective utilization of NHS resources. Lucentis has also been recommended for the treatment of vision impairment as a result of macular edema associated with RVO According to the report, the Global Macular Edema market is driven by several factors, of which the increase in the patient population is one of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD, inflammatory conditions such as uveitis, and RVO cause macular edema. The increase in the incidence and prevalence of ophthalmological conditions such as AMD and DR is expected to increase the patient population with macular edema during the forecast period. Further, the report states that although the Global Macular Edema market has several drivers, the growth of the market is curtailed by some serious challenges. One of the main challenges is increased use of off-label drugs. Use of off-label drugs increases the market competition for approved branded drugs. Some of the off-label drugs for the treatment of macular edema are bevacizumab, topical NSAIDs, and drugs such as acetazolamide. The report also includes a discussion of the other vendors operating in this market. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Alcon Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - iCo Therapeutics Inc. - Pfizer Inc. - Santen Pharmaceutical Co. Ltd. For more information visit http://www.researchandmarkets.com/research/6c...al_macular
AGN: 312.13 (+8.03), ALIM: 4.56 (+0.15), PFE: 34.36 (+0.50), AMPE: 2.51 (+0.24), REGN: 526.01 (+16.98), NVS: 103.22 (+3.20)
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
ALIM: 4.56 (+0.15), BMY: 69.27 (+1.38), REGN: 526.01 (+16.98), VRX.TO: 294.65 (+11.22), NVS: 103.22 (+3.20)
Ocular Hypertension - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nbvbk4/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerie Pharmaceuticals, Inc. - Allergan, Inc. - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - Can-Fite BioPharma Ltd. - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Merck & Co., Inc. - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. For more information visit http://www.researchandmarkets.com/research/nbvbk4/ocular
CANF: 2.00 (+0.09), AGN: 312.13 (+8.03), ITEK: 5.11 (+0.25), MRK: 57.95 (+0.57), AERI: 17.80 (+0.12), OCUL: 20.82 (+0.73)
Uveitis Pipeline Review, H1 2015
M2 - Thu Jun 11, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xvvmhf/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aciont Inc. - Apitope International NV - BBB Therapeutics B.V. - Can-Fite BioPharma Ltd. - Clearside BioMedical, Inc. - Effimune SAS - Eleven Biotherapeutics Inc. - Endocyte, Inc. - Enzo Biochem, Inc. - EyeGate Pharmaceuticals, Inc. - ForSight VISION4, Inc. - HanAll Biopharma Co., Ltd. - Icon Bioscience, Inc. - IMMD Inc. - Johnson & Johnson - Neuroptis Biotech - Novartis AG - Ocata Therapeutics, Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. - Pfizer Inc. - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SynDevRx, Inc. - TxCell SA - Virogenomics, Inc. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/xvvmhf/uveitis
OCAT: 5.22 (+0.14), PFE: 34.36 (+0.50), CANF: 2.00 (+0.09), JNJ: 99.53 (+1.13), ECYT: 5.43 (+0.17), ENZ: 3.00 (+0.04), ABBV: 69.23 (+1.26), REGN: 526.01 (+16.98), XOMA: 4.72 (+0.23), NVS: 103.22 (+3.20)
Global Acute Pain Pipeline Report 2015
M2 - Thu Jun 04, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gndxls/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt plc - MEDRx Co., Ltd. - Merck & Co., Inc. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Rottapharm SpA - Santen Pharmaceutical Co., Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. - Thar Pharmaceuticals, Inc. - Trevena, Inc. - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/gndxls/acute_pain
ACRX: 4.20 (+0.02), TRVN: 6.51 (+0.61), KMPH: 17.95 (-0.08), MRK: 57.95 (+0.57), PCRX: 67.54 (+0.20), NKTR: 11.40 (+0.22)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015
M2 - Wed May 27, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vmksm/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - EyeGate Pharmaceuticals, Inc. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kainos Medicine, Inc. - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Neuroptis Biotech - NovaBay Pharmaceuticals, Inc. - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - SIFI S.p.A For more information visit http://www.researchandmarkets.com/research/3v...njunctivit
OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), CLTX: 0.49 (-0.02)
Santen Announces Assignment of Its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma Co., Ltd.
GlobeNewswire - Tue May 12, 2:53AM CDT
Santen Pharmaceutical Co., Ltd. ("Santen"
announced today that it has resolved at its board of directors meeting held on May 12, 2015 to enter an agreement with Showa Yakuhin Kakou Co., Ltd. ("Showa Yakuhin" and Hyperion Pharma Co., Ltd. ("Hyperion" to assign its anti-rheumatic pharmaceuticals business to Hyperion, under a simplified company-split method under the Company Act of Japan ("Assignment" . On the same date, Santen, Hyperion, and Showa have entered into the agreement on the Assignment. Santen Reports Consolidated Performance for the Fiscal Year Ended March 31, 2015
GlobeNewswire - Tue May 12, 2:53AM CDT
Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange Code:4536) (Santen) today announced consolidated performance for fiscal 2014 (ended March 31, 2015) as well as guidance for fiscal 2015 (ending March 31, 2016).
R-Tech Ueno: Announcement on Acquisition of the Right to Develop and Commercialize DE-105 from Santen Pharmaceutical Co., Ltd.
Business Wire - Mon Apr 27, 2:03AM CDT
R-Tech Ueno (JASDAQ:4573)
Santen Announces Approval of Ikervis for EU Marketing Authorization
GlobeNewswire - Wed Mar 25, 3:45AM CDT
Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European Commission (EC). Ikervis is approved for treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.
European Medicines Agency Accepts Santen's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment
GlobeNewswire - Mon Mar 02, 2:24AM CST
Santen Pharmaceutical Co., Ltd. announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Application (MAA) filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment. The MAA filing marks the beginning of a regulatory review process for intravitreal sirolimus, which has the potential to address an unmet need in the European Union (EU) where NIU of the posterior segment is a leading cause of blindness.
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 5.22 (+0.14), ITEK: 5.11 (+0.25), NBS: 2.25 (-0.09), FOMX: 11.18 (+0.22), AERI: 17.80 (+0.12), OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), CANF: 2.00 (+0.09), ACAD: 43.94 (+1.76), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), OHRP: 2.27 (-0.07), CBMG: 29.80 (+0.31)
DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product
PR Newswire - Tue Dec 16, 7:00AM CST
DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's SABER® technology to deliver an ophthalmology drug.
DRRX: 2.48 (+0.15)
Increase of Capital for a Consolidated Subsidiary in Europe
GlobeNewswire - Thu Sep 25, 4:32AM CDT
Santen Pharmaceutical Co., Ltd. (Osaka, hereinafter "Santen"
hereby announces that it was resolved at the Board of Director meeting held on September 25, 2014 to increase capital for Santen Holdings EU B.V., a consolidated wholly owned holding company in Europe. Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 17.80 (+0.12)
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
CANF: 2.00 (+0.09), ECYT: 5.43 (+0.17), ENZ: 3.00 (+0.04), PFE: 34.36 (+0.50), ABBV: 69.23 (+1.26), XOMA: 4.72 (+0.23), NVS: 103.22 (+3.20)
Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Aug 12, 6:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6chxqf/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering. The Global Macular Edema market will grow at a CAGR of 9.1% over the period 2014-2018. NICE issues and updates technology appraisals and clinical guidelines to recommend appropriate and effective treatments for different diseases. It plays a role in increasing drug sales. In January 2013, NICE recommended Lucentis for the treatment of DME. This recommendation superseded the November 2011 guidance, which concluded that recommending Lucentis was not effective utilization of NHS resources. Lucentis has also been recommended for the treatment of vision impairment as a result of macular edema associated with RVO According to the report, the Global Macular Edema market is driven by several factors, of which the increase in the patient population is one of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD, inflammatory conditions such as uveitis, and RVO cause macular edema. The increase in the incidence and prevalence of ophthalmological conditions such as AMD and DR is expected to increase the patient population with macular edema during the forecast period. Further, the report states that although the Global Macular Edema market has several drivers, the growth of the market is curtailed by some serious challenges. One of the main challenges is increased use of off-label drugs. Use of off-label drugs increases the market competition for approved branded drugs. Some of the off-label drugs for the treatment of macular edema are bevacizumab, topical NSAIDs, and drugs such as acetazolamide. The report also includes a discussion of the other vendors operating in this market. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Alcon Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - iCo Therapeutics Inc. - Pfizer Inc. - Santen Pharmaceutical Co. Ltd. For more information visit http://www.researchandmarkets.com/research/6c...al_macular
AGN: 312.13 (+8.03), ALIM: 4.56 (+0.15), PFE: 34.36 (+0.50), AMPE: 2.51 (+0.24), REGN: 526.01 (+16.98), NVS: 103.22 (+3.20)
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
ALIM: 4.56 (+0.15), BMY: 69.27 (+1.38), REGN: 526.01 (+16.98), VRX.TO: 294.65 (+11.22), NVS: 103.22 (+3.20)
